Amylyx Pharmaceuticals Inc

AMLX

Equity

ISIN null / Valor 115580129

NASDAQ (2025-11-19)

USD 14.32+2.65%

Amylyx Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Amylyx Pharmaceuticals Inc is a biopharmaceutical company focused on developing therapies for neurodegenerative diseases, with a particular focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease.

Summarized from source with an LLMView SourceSector: Healthcare

Research and Development Expenses

R&D expenses for Q2 2025 were $27.2 million, up from $23.3 million in Q2 2024. The increase was primarily driven by the clinical development of avexitide for PBH and AMX0035 for PSP, partially offset by reduced spending on AMX0035 in ALS. Stock-based compensation included $2.0 million in Q2 2025 compared to $2.4 million in the previous year.

Selling, General, and Administrative Expenses

SG&A expenses decreased to $15.6 million in Q2 2025 from $21.6 million in Q2 2024. This reduction was mainly due to lower payroll and personnel costs, as well as decreased spending on consulting and professional services. Stock-based compensation for SG&A was $5.4 million in Q2 2025, down from $7.1 million in Q2 2024.

Net Loss

The company reported a net loss of $41.4 million, or $0.46 per share, for Q2 2025, compared to a net loss of $72.7 million, or $1.07 per share, in Q2 2024. This improvement reflects better management of expenses and operational efficiencies.

Cash Position

Amylyx Pharmaceuticals Inc. held $180.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, down from $204.1 million at the end of Q1 2025. The current cash runway is expected to sustain operations through the end of 2026.

Summarized from source with an LLMView Source

Key figures

174%1Y

-59.1%3Y

%5Y

Performance

78.3%1Y

123%3Y

123%5Y

Volatility